Cardiac Catheterization Laboratory 2014, Department of Medicine B, Faculty of Health Sciences, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark.
Inflamm Res. 2011 Mar;60(3):281-7. doi: 10.1007/s00011-010-0266-5. Epub 2010 Oct 23.
The inflammatory biomarker YKL-40 is elevated and associated with mortality in patients with stable coronary artery disease (CAD). The aim was to investigate the influence of statin treatment and lipid status on serum YKL-40 and Hs-CRP in patients with stable CAD.
Serum YKL-40, HsCRP, total cholesterol, HDL-c, LDL-c and triglycerides levels were measured in 404 statin treated and in 404 matched non-statin treated patients with stable CAD.
YKL-40 was significantly higher in non-statin treated 110 µg/l (median) compared with 65 µg/l in statin treated (p < 0.001). HsCRP was 3.3 mg/l in non-statin treated compared with 2.1 mg/l in statin treated (p < 0.001). YKL-40 was not related to cholesterol levels for either statin or non-statin treated patients in the univariate analysis. In statin treated patients, HsCRP was related to a high level of total-cholesterol (p = 0.01) and a low level of HDL-c (p < 0.001).
HsCRP, but not YKL-40, is associated with the cholesterol levels in statin treated patients. This indicates that YKL-40 could be a superior prognostic biomarker in patients with stable CAD, since it is independent of changes in cholesterol levels in both statin and non-statin treated patients.
YKL-40 是一种炎症生物标志物，在稳定性冠心病（CAD）患者中升高并与死亡率相关。本研究旨在探讨他汀类药物治疗和血脂状况对稳定性 CAD 患者血清 YKL-40 和 Hs-CRP 的影响。
测量了 404 例接受他汀类药物治疗的患者和 404 例匹配的未接受他汀类药物治疗的稳定性 CAD 患者的血清 YKL-40、HsCRP、总胆固醇、HDL-c、LDL-c 和甘油三酯水平。
未接受他汀类药物治疗的患者 YKL-40 水平明显高于接受他汀类药物治疗的患者（中位数分别为 110μg/l 和 65μg/l，p<0.001）。未接受他汀类药物治疗的患者 HsCRP 水平为 3.3mg/l，而接受他汀类药物治疗的患者为 2.1mg/l（p<0.001）。在单因素分析中，YKL-40 与他汀类或非他汀类治疗患者的胆固醇水平均无相关性。在接受他汀类药物治疗的患者中，HsCRP 与总胆固醇水平升高（p=0.01）和 HDL-c 水平降低（p<0.001）相关。
HsCRP 而不是 YKL-40 与他汀类药物治疗患者的胆固醇水平相关。这表明 YKL-40 可能是稳定性 CAD 患者的一种更好的预后生物标志物，因为它独立于他汀类和非他汀类治疗患者胆固醇水平的变化。
